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Abstract
Background: The lack of positive costimulatory molecules represents one of the mechanisms by which tumor cells
evade immune surveillance. Promoter hypermethylation plays a major role in cancer development through
transcriptional silencing of critical genes. The aim of this study was to examine the expression of the costimulatory
molecule CD80 in relationship with genomic methylation in non-inflammatory colon carcinogenesis.
Methods: Colonic mucosal samples were collected from healthy subjects (n = 30) and from dysplastic adenoma (n = 14),
and colon adenocarcinoma (n = 10). DNA methyltransferases-1, −3a, −3b and CD80 mRNA expression were quantified by
real time qRT-PCR. The methylation status of CDH13, APC, MLH1, MGMT1 and RUNX3 gene promoters was assessed by
methylation-specific PCR. CD80 expression was assessed in HT29, HCT-15 and LoVo cell lines after treatment with the
DNA-methyltransferase inhibitor 5-Aza-2′-deoxycytidine.
Results: CD80 mRNA levels were significantly lower in the non-inflammatory dysplastic colonic mucosa of patients with
one or more methylated genes and inversely correlated with patients’ methylation scores (τ = −0.41, p = 0.05 and τ = −0.
37, p = 0.05, respectively). Treatment with 5-Aza-2′-deoxycytidine significantly increased CD80 expression both in terms of
the level of CD80 mRNA (p = 0.007) and of CD80+ cells (p = 0.003).
Conclusions: These results indicate that the failure of immune surveillance mechanisms in non-inflammatory colon
carcinogenesis may be linked to genomic methylation directly or indirectly affecting CD80 expression.
Background
Immune surveillance of nascent cancer cells is a funda-
mental process mediated by T-cells, macrophages, and
natural killer cells that work to protect host against the
unrestrained proliferation of transformed cells [1]. Full
T-cell activation requires the engagement of T-cell re-
ceptors with specific major histocompatibility complexes
at the surface of antigen-presenting cells in the presence
of adequate co-stimulatory signals provided by CD80 or
CD86 [2]. Oncogenic insults inducing CD80 expression
seem then to be able to modulate the anti-tumor im-
mune response [3]. The significant overexpression of
CD80 in the colonic mucosa of patients with ulcerative
colitis (UC) and dysplasia as opposed to CD80 down-
regulation in non-inflammatory colon cancer [4–6] have
led to the hypothesis that the lack of positive co-
stimulatory molecules is one of the main mechanisms by
which colorectal cancer (CRC) escapes immune surveil-
lance [7]. The molecular mechanisms underlying immune
surveillance remain, nevertheless, largely unknown.
An altered methylation pattern in cancer cell genomes
is a well recognized characteristic of tumor cells, and
specific aberrant methylation events take place during
the early stages of colorectal carcinogenesis leading to
profound modifications in gene expression [8]. The aber-
rant methylation of H-cadherin (CDH13) commencing
at an early stage of colorectal tumorigenesis frequently
silences, in fact, the expression of this tumor suppressor
gene in colorectal adenomas and cancers [9]. Besides
germ-line mutations associated with hereditary familial
adenomatous polyposis and somatic mutations in sporadic
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colorectal tumors, hypermethylation also provides an im-
portant mechanism underlying impaired APC function
[10]. Moreover, the hypermethylation of the CpG island
within the DNA-repair protein O-6-methylguanine-DNA-
methyltransferase (MGMT) gene [11] and in the MLH1
gene is associated with a reduced gene expression ob-
served in the majority of sporadic primary CRC with
microsatellite instability [12]. Finally, RUNX3 hyperme-
thylation decreases TGF-β/BMP signaling in gastrointes-
tinal cancer cells [13].
In addition to oncogenes or oncosuppressors, some
immune stimulatory molecules are regulated in cancer
cells by DNA methylation in their promoter regions.
MHC class I and its antigen presentation machinery
have been shown to be regulated by DNA methylation
[14–17]. Adhesion molecules [14–18], such as ICAM-1
and LFA-3, and costimulatory molecules [17, 18], such
as CD40 and CD86, can be regulated by DNA methyla-
tion in cancer cells. Thus, demethylation treatment can
dramatically increase the susceptibility of some tumor
cells to T-cell destruction [15, 19–21]. Our first step in
investigating the role of DNA methylation in CRC im-
mune surveillance consisted in examining the expression
of CD80; we then went on to analyze its relationship




A prospective cohort study of healthy controls (n = 30)
and patients (n = 24) who underwent colonoscopy for
screening or post-operative follow-up or colonic resec-
tion for colorectal cancer was designed. Biopsy samples
of healthy mucosa (n = 30), of normal and diseased mu-
cosa from patients with dysplastic adenoma (n = 14), and
from patients with colon adenocarcinoma (n = 10, one
patients staged T1N0M0, two T2N0M0, two T3N0M0,
four T3N1M0 and one T3N1M1) were collected.
Patients’ and controls’ characteristics are outlined in
Table 1.
Gene expression analysis
Total RNA was extracted using the RNeasy Plus Kit
(Qiagen) according to the manufacturer’s protocol. At
that point 0.5 μg total RNA was converted to cDNA
using the Applied Biosystems cDNA Synthesis kit, again,
according to the manufacturer’s instructions. DNA
methyltransferase-1, −3a, −3b (DNMT-) and CD80
mRNA expression was quantified by real time qRT-PCR.
Specific mRNA transcripts were quantified with SYBR
Green PCR Master Mix in a ABI PRISM 7000 Sequence
Detection System (Applied Biosystems). ACTB expression
was used as reference gene for normalization. Primer
sequences and PCR conditions are outlined in Table 2.
Methylation specific PCR
Genomic DNA was extracted from tissues using a
DNeasy Blood & Tissue Kit (Qiagen) according to the
manufacturer’s directions. Sodium bisulfate modification
of gDNA was performed using the EZ DNA
Methylation-Gold Kit (Zymo Research) following the
manufacturer’s instructions. The primers for APC,
CDH13, MGMT, MLH1 and RUNX3 methylation-
specific PCR and PCR conditions are outlined in Table 2.
The EpiTect PCR Control DNA Set (Qiagen) was used
as the positive control for the methylated and unmethy-
lated genes. Each PCR was done in a final volume of
25 μL containing 10 ng of bisulfite converted gDNA, 1×
PCR buffer, 0.25 mmol/L deoxynucleotide triphosphate,
400 nmol/L each primer, and 1 unit ZymoTaq (Zymo
Research). PCR amplification was done as follows: 95 °C
for 10 min followed by 40 cycles at 95 °C for 30 s, the
specific annealing temperature for each gene for 30 s
and 72 °C for 30s; and, in a final extension step, at 72 °C
for 7 min. PCR products were resolved by 3 % agarose
gel electrophoresis and each case was scored as
Table 1 Patients characteristics
Non-inflammatory carcinogenesis Healthy controls Adenoma and dysplasia Cancer
Patients (n) 30 14 10
median age (range) 59.5 (52–69) years 61 (51–69) years 63 (49–74) years
gender (male/female) 14:16 7:7 7:3
procedures colonoscopy: 30 colonoscopy: 12 colonic resection: 8
RPC: 2 rectal resection: 2
carcinogenesis stage NA LGD: 9 T1N0M0: 1




HGD high grade dysplasia, LGD low grade dysplasia, RPC restorative proctocolectomy
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methylated or unmethylated. Since we aimed to investi-
gate the role of any grade of methylation, we considered
as methylated those sample showing any detectable spe-
cific band. The patients’ global methylation scores were
calculated by summing the number of methylated genes
(range 0–5).
CD80 expression in intestinal epithelial cell lines
Three colorectal adenocarcinoma cell lines were used in
the present study. HCT-15, HT-29 and LoVo were pur-
chased from the American Tissue Culture Collection, cul-
tured in medium (DMEM for HCT-15 and HT29, Ham’s
F12 Nutrient Mixture for LoVo) supplemented with 10 %
FBS and 1X pen/strep solution (all from Life Technologies)
and maintained in humidified 37 °C 5 % CO2 incubators ac-
cording to the manufacturer’s protocol. Fifty percent con-
fluent cells were incubated with the DNA methyltransferase
inhibitor 5-Aza-2′-deoxycytidine (5AZAdC) (5 μM, Sigma)
or vehicle as a control for 96 h. Cells were harvested for
Real-time qPCR or flow cytometric analysis.
Flow cytometry
HT29, HCT-15 and LoVo cells were stained with CD80-
FITC antibody (clone 2D10, eBioscience) in staining
Table 2 Real-Time qPCR and Methylation-Specific PCR primers
Real-Time qPCR primers
Gene NCBI ref seq Sequence 5'– > 3' Ta, °C Amplicon, bp
Actb NM_001101 fw CTGGACTTCGAGCAAGAGATG 60 180
rv AGTTGAAGGTAGTTTCGTGGATG
Cd80 NM_005191 fw CTCACTTCTGTTCAGGTGTTATCCA 62 121
rv TCCTTTTGCCAGTAGATGCGA
Dnmt1 NM_001130823 fw TACCTGGACGACCCTGACCTC 60 103
rv CGTTGGCATCAAAGATGGACA
Dnmt3a NM_175629 fw GACAAGAATGCCACCAAAGC 60 190
rv CGTCTCCGAACCACATGAC
Dnmt3b NM_006892 fw GGCAAGTTCTCCGAGGTCTCTG 60 113
rv TGGTACATGGCTTTTCGATAGGA
Methylation specific PCR primers
Gene sequence 5'– > 3' Ta,°C Amplicon, bp
CDH13 meth Fw TCGCGGGGTTCGTTTTTCGC 66 243
Rv GACGTTTTCATTCATACACGCG
CDH13 unmeth Fw TTGTGGGGTTGTTTTTTGT 55 242
Rv AACTTTTCATTCATACACACA
APC meth Fw TATTGCGGAGTGCGGGTC 64 98
Rv TCGACGAACTCCCGACGA
APC unmeth Fw GTGTTTTATTGTGGAGTGTGGGTT 62 108
Rv CCAATCAACAAACTCCCAACAA
RUNX3 meth Fw TTACGAGGGGCGGTCGTACGCGGG 71 220
Rv AAAACGACCGACGCGAACGCCTCC
RUNX3 unmeth Fw TTATGAGGGGTGGTTGTATGTGGG 64 220
Rv AAAACAACCAACACAAACACCTCC
MGMT meth Fw TTTCGACGTTCGTAGGTTTTCGC 64 81
Rv GCACTCTTCCGAAAACGAAACG
MGMT unmeth Fw TTTGTGTTTTGATGTTTGTAGGTTTTTGT 64 93
Rv AACTCCACACTCTTCCAAAAACAAAACA
MLH1 meth Fw ACGTAGACGTTTTATTAGGGTCGC 56 115
Rv CCTCATCGTAACTACCCGCG
MLH1 unmeth Fw TTTTGATGTAGATGTTTTATTAGGGTTGT 56 124
Rv ACCACCTCATCATAACTACCCACA
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buffer (PBS with 1 % FBS) on ice for 30 min. Flow cyto-
metric analysis was performed by a FACScalibur flow
cytometer using CellQuest software (Becton Dickinson).
Statistical analysis
Data are shown as mean ± SEM. Non-parametric
Mann–Whitney’s U-test was carried out to compare in-
dependent variables, the Wilcoxon test was used to
compare matched variables, and the Kruskal-Wallis
ANOVA was performed to compare multiple variables.
The Kendall rank correlation test was applied. Differ-
ences were considered significant at p < 0.05.
Results
Methylation status of gene promoters involved in the
early stages of colon carcinogenesis
The promoter methylation status of five genes known to
be associated with early stages of colon carcinogenesis
was assessed in the colonic mucosa of 54 subjects
(Table 1). They consisted of 30 healthy controls, 14 with
adenoma and dysplasia, and 10 with colorectal adenocar-
cinoma. The promoter regions of APC, CDH13, MGMT1
and RUNX3 were more frequently methylated in patients
with invasive adenocarcinoma (p = 0.04, p = 0.02, p = 0.03
and p = 0.05, respectively) (Fig. 1a). Consequently, the
methylation score was significantly higher in patients with
cancer than those with pre-neoplastic lesions (i.e. aden-
omas) and healthy subjects (p = 0.04) (Fig. 1b).
CD80 and DNMTs mRNA expression along colonic
carcinogenesis pathway
The expression of CD80 and methyltransferase
(DNMT)-1, −3a, and −3b was quantified in the different
steps of sporadic carcinogenesis. CD80 mRNA expres-
sion did not show any significant variation as shown in
Fig. 2a. On the other hand, in colonic lesions the expres-
sion of all three DNMTs tended to increase progressively
along the carcinogenesis pathways, as shown in Fig. 2b-d.
Relationship between the methylation status, DNMTs and
CD80 expression in colon carcinogenesis
As shown in Fig. 3, CD80 mRNA levels were inversely
correlated with the DNMT3A mRNA levels in healthy
colonic mucosa of patients with adenoma and with
Fig. 1 Methylation status of gene promoters involved in the early
stages of colon carcinogenesis. a The methylation status of APC,
CDH13, MGMT, MLH1 and RUNX3 gene promoters was assessed by
methylation specific-PCR of colonic mucosa specimens derived from
patients with colon carcinogenesis. The frequency of methylation of each
gene among the different patients groups is shown. b The frequency of
total methylation, defined as the sum of the methylated genes detected
(range 0–4), among the different patients groups is shown. CTRL, healthy
control; DYS, dysplasia and adenoma
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DNMT3B in healthy colonic mucosa of patients with
cancer (τ = −0.44, p = 0.07 and τ = −0.50, p = 0.04, re-
spectively). Moreover, in colonic adenoma CD80 mRNA
levels resulted inversely correlated to the number of
methylated genes (τ = −0.43, p = 0.04).
DNA methylation affects CD80 expression in intestinal
epithelial cells
To assess the impact of DNA methylation on CD80 gene
expression levels in intestinal cancer cells, HT29,
HTC15 and LoVo cell lines were treated with 5AZAdC,
the DNMTs inhibitor. As shown in Fig. 4a and b, at
basal levels CD80 mRNA was barely detectable and the
percentage of CD80+ HT29, HTC15 and LoVo cells
was < 2 %. Adding 5AZAdC to HT29, HTC15 and
LoVo cells coltures significantly increased CD80 expression
both in terms of CD80 mRNA levels (p = 0.005, p = 0.02
and p = 0.02, respectively) and of CD80+ cells (p = 0.001,
p = 0.02 and p = 0.04, respectively).
Discussion
Cancer immune surveillance is a fundamental process by
which immune cells protect against cancer formation by
identifying and eliminating tumor cells on the basis
of their expression of tumor-specific and stress-
induced antigens [1]. While it has been suggested that
the lack of positive co-stimulatory molecules is the
mechanism by which tumor cells evade immune sur-
veillance, the molecular events underlying this process
remain elusive.
Fig. 2 CD80 and DNA methyltransferases mRNA levels in colon carcinogenesis. a CD80, (b) DNMT1, (c) DNMT3a and (d) DNMT3b mRNA levels
were quantified by Real Time qPCR in the colonic mucosa specimens of patients with non-inflammatory colon carcinogenesis; mRNA
mean levels ± SEM in the different patients groups are shown. Kruskal-Wallis ANOVA test was performed to compare multiple groups.
CTRL, control; DYS, dysplasia and adenoma
Fig. 3 Relationship between the methylation status and CD80 in colon carcinogenesis. Correlation analysis of CD80 mRNA expression with
DNMTs expression and DNA methylation status. The heat-map depicts correlation coefficient τ calculated using Kendall rank analysis. *p < 0.05
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In this study, we show that CD80 mRNA expression,
the co-stimulatory molecule found in colon carcinogen-
esis, inversely correlates with the inducible DNMTs
expression in healthy tissue of patients with adenoma or
cancer and with the number of genes that have promoters
which are often aberrantly hypermethylated at early stages
of colorectal tumorigenesis and, as a consequence,
thought to contribute to CRC pathogenesis [8]. Indeed,
APC, CDH13, MGMT1 and RUNX3 methylation fre-
quency of gene promoters as well as DNMTs expression
progressively increases along the pathway towards invasive
cancer in sporadic colonic carcinogenesis. Taken together
these data suggest that DNA methylation plays a role in
CD80 expression. This association has been found to be
notable at the dysplastic stage of carcinogenesis when the
CD80-driven immune surveillance process might be crit-
ical in preventing cancer cells from escaping [6, 22]. But
although two prospective studies characterized by ad-
equate follow-up and precise definition of the adenoma
site failed to show complete regression or spontaneous re-
duction of polyps [23, 24], the findings of a more recent
epidemiological investigation suggest that dysplastic aden-
oma prevalence in humans is caused by a dynamic process
including both adenoma formation and regression [25].
Our data are, indeed, the first to suggest that DNA
methylation of CD80 gene may explain why immune
surveillance mechanisms can at times fail in patients
with non-inflammatory colorectal carcinogenesis.
Interestingly, a recent investigation reported hyperme-
thylation of the CD80 promoter in mice tumours, and
treatment with decitabine, a DNA methyltransferase
inhibitor, was found to enhance CD80 expression in EL4
cells via demethylation of CpG dinucleotide sites in the
promoter of CD80 gene resulting in T lymphocyte infil-
tration into tumors and, ultimately, in tumor rejection
[26]. Likewise, epigenetic silencing of CD70, a CD80 re-
lated co-stimulatory molecule, by DNA methylation was
noted during breast cancer progression in an in vitro
model [27].
Our in vitro assay on HT29, HTC15 and LoVo CRC
cell lines further supports the hypothesis that DNA
methylation is involved in the inhibition of the gene ex-
pression of CD80. There was, in fact, a 10-fold increase
in CD80 mRNA levels and the number of CD80+ cells
was doubled following treatment with a DNA methyl-
transferase inhibitor. These data are particularly relevant
because they confirm the hypothesis of a role of gene
methylation in the inhibition of CD80 expression in
three different CRC cell lines.
A limit of the present study is the lack of a direct evidence
of DNA methylation of the CD80 promoter. Usually, but
not exclusively, methylation occurs at the so-called CpG
islands and if hypermethylation involves the promoter region
it may result in gene silencing. CD80 promoter do not con-
tain any sequence with characteristics making methylation
easy to detect (CD80 at chr3:119524293-119559634 Genome
Browser http://genome.ucsc.edu/index.html). Given the diffi-
culty in directly assessing whether and at what stage CD80
methylation takes place along the colorectal carcinogenesis
pathway and in order to assess if hypermethylation plays a
role in CD80 down-regulation in human colorectal tumori-
genesis, we examined the correlation between expression of
CD80 and the methylation of genes involved in the early
stages of CRC carcinogenesis and the expression of DNMTs
and attempted to verify our hypothesis by developing an
in vitro assay. Finally, this study did not explore the interac-
tions of CD80 and PD-1 with B7H1 (programmed death
ligand 1 [PD-L1]) [28]. In fact, although they are both
located on antigen presenting cells’ surface, CD80 also
has an appreciable affinity for the PD-L1 [29]. Their
interplay has a pivotal role in controlling T cell activa-
tion, proliferation, anergy, and apoptosis and methyla-
tion might play a role in their regulation. However, the
interactions between the two pathways remain still
unknown.
Fig. 4 DNMTs inhibition triggers CD80 expression in intestinal
epithelial cells. LoVo, HCT15 and HT29 cells were cultered in the
presence or not of the DNMTs inhibitor 5AZAdC for 96 h, then cells
were harvested for analysis. a Cd80 mRNA was quantified by Real
Time qPCR and (b) CD80 protein expression was evaluated by flow
cytometry. The mean ± SEM is represented (n = 8)
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Conclusion
In conclusion, gene methylation seems to be associated
to the CD80 down-regulation observed in dysplasia of
sporadic colonic carcinogenesis. In vitro inhibition of
DNA methyltransferases significantly enhances CD80
expression in colon cancer cells. We hypothesize that
the failure of immune surveillance mechanisms in
colonic non-inflammatory carcinogenesis is linked to
genomic methylation directly or indirectly affecting
CD80 expression.
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